- Bio Protocol’s native token (BIO) surged 56% to $0.1238 within 24 hours after being listed on Upbit, South Korea’s leading crypto exchange.
- A network upgrade introduced advanced AI-driven BioAgents, added multichain support, and delivered other important ecosystem improvements for Bio Protocol.
- BIO’s market capitalization rose to $196 million.
Bio Protocol’s native token experienced a dramatic rally, jumping 56% over a 24-hour period to reach $0.1238, with trading volume surpassing $164 million.
This sharp upturn followed the token’s recent listing on Upbit, the premier South Korean crypto platform.
Bio Protocol price soars amid Upbit listing
After a month of decline, Bio Protocol (BIO) is showing signs of recovery.
Since October 1, the cryptocurrency had been in a steady downtrend, falling from $0.15 to a low near $0.078.
The announcement of BIO’s Upbit listing served as the immediate catalyst for the token’s explosive growth.
Upbit accounts for over 80% of South Korea’s crypto trading volume and has a track record of propelling altcoins to new highs.
At the time of writing, BIO’s trading volume surged 820% over the past 24 hours to $311.55 million.
This new listing builds on BIO’s momentum following earlier listings on Binance and Kraken.
BIO is currently trading around $0.11 after breaking resistance at $0.09, and its market capitalization is now approximately $196 million, according to CoinMarketCap data.
Price chart for Bio Protocol by CoinMarketCap
However, traders warn of potential pullbacks if broader market corrections occur, underlining the need for sustainable adoption beyond short-term hype.
Network upgrade fuels interest
In addition to the Upbit listing, ongoing excitement surrounds Bio Protocol’s recent major network upgrade.
The update further energized the project’s community.
The upgrade includes improvements to Bio Protocol’s staking mechanisms.
It also integrates BioAgents—AI-powered research assistants designed to automate hypothesis generation and experiment tracking.
“From AI co-scientists to biotech intellectual property, more than 8,000 participants joined the first wave of new Bio Launchpad projects. These launches are backed by tokenized AI co-scientists and biotech IP, enabling communities to fund and own breakthroughs in stem cell research, men’s health and brain health. Each project leveraged on-chain treasuries and liquidity, laying the groundwork for communities aligned by incentives around real-world science.”
While some issues, such as temporary network slowdowns, may affect short-term outlooks, Bio Protocol’s ability to connect biotech innovation with decentralized governance represents a significant opportunity for BIO.
The project is redefining industry standards and offering investors a unique chance to participate in a transformative ecosystem.
Stakeholders are advised to monitor upcoming milestones, including the rollout of new BioXP rewards and further cross-chain developments.
Prevailing market conditions could pose headwinds to continued upside.
Still, with new listings and additional initiatives underway, buyers may target levels near $0.43, beyond which the all-time high of $0.92 reached in January 2025 could come into view.